Clinical Trials

Thoracical Tumors

Recruitment stopped
Ongoing Recruitment

GO adjuvant 29527 / GO29527

(adjuvant)
Title:A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Indication:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02486718
EudraCT: 2014-003205-15 (siehe EU klinisches Studienregister)

CINC wt-Studie (Novartis CINC280A2201)

(second-line)
Title:A Phase II, Multicenter, Three-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02414139
EudraCT: NCT02414139 (siehe EU klinisches Studienregister)

BioNTech –Forschungsstudie (RB_T002)

(diagnostisch, Früherkennung, Screening)
Title:Identifikation von individuellen Krebsmutationen und Testung ihrer Immunogenität
Indication:-
Type of study:Phase N/A
Contact: Anette Manka-Stuhlik (Study Nurse)
[anette.manka-stuhlik@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Dirk Jäger (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PET-CT__PET-MRT bei BC

(diagnostisch, Screening)
Title:Vergleich der diagnostischen Genauigkeit von FDG-PET/CT und FDG-PET/MRT einschließlich Diffusionsgewichteter MRT beim präoperativen Staging von Patienten mit Nicht-kleinzelligem Bronchialkarzinom.
Indication:n.a.
Type of study:Phase N/A
Contact: Radiologie DKFZ (Kontaktperson)
[-]
Investigator: Prof. Dr. Heinz-Peter Schlemmer (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

INKA-Studie

(radiologisch)
Title:Ionentherapie bei nicht-kleinzelligen Pancoast-Tumoren im trimodalen Behandlungskonzept: Die INKA-Studie
Indication:Lunge
Type of study:Phase N/A
Contact: Prof. Dr. med. Jürgen Debus (Kontaktperson)
[juergen.debus@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Klaus Herfarth (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

ATLANTIS (PM1183-C-003-14)

Title:Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02566993
EudraCT: 2015-004861-97 (siehe EU klinisches Studienregister)

BV-NSCLC-002 / BIOVEN 2

Title:Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02187367
EudraCT: 2013-005335-25 (siehe EU klinisches Studienregister)

D419QC00001 / CASPIAN

Title:A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
Indication:CarcinomaLung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03043872
EudraCT: 2016-001203-23 (siehe EU klinisches Studienregister)

DURATION / AIO-YMO/TRK-0416

Title:Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Indication:CarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinoma
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03345810
EudraCT: 2016-003963-20 (siehe EU klinisches Studienregister)

EMR 100070-005 / JAVELIN Lung

Title:A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02576574
EudraCT: 2015-001537-24 (siehe EU klinisches Studienregister)

FORCE

Title:Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
Indication:CarcinomaLung NeoplasmsAdenocarcinomaCarcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr.med. Farastuk Bozorgmehr (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03044626
EudraCT: 2015-005741-31 (siehe EU klinisches Studienregister)

HeiMeKom

Title:Heidelberger Meilenstein-Kommunikationskonzept (HeiMeKOM) - Eine Mixed-Method Studie
Indication:Metastasiertes Lungenkarzinom
Type of study:Phase N/A
Contact: Anja Siegle (Kontaktperson)
[Anja.Siegle@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Leiter klinische Prüfung)
Trial Register: Die Studie ist beim "DRKS - Deutsches Register Klinischer Studien" registriert. Siehe DRKS00013469
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

MERU / M16-298

Title:A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Indication:Lung Neoplasms Small Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03033511
EudraCT: 2016-003503-64 (siehe EU klinisches Studienregister)

MK-3475-604 / Pembro SCLC

Title:A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03066778
EudraCT: 2016-004309-15 (siehe EU klinisches Studienregister)

POSEIDON / D419MC00004

Title:A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC)
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03164616
EudraCT: 2017-000920-81 (siehe EU klinisches Studienregister)

Pembro Ipi Firstline / MK-3475-598

Title:A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS = 50%) (KEYNOTE-598)
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03302234
EudraCT: 2016-004364-20 (siehe EU klinisches Studienregister)

Pfizer Lorlatinib / B7461006

Title:A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03052608
EudraCT: 2016-003315-35 (siehe EU klinisches Studienregister)

TAHOE / M16-289

Title:A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03061812
EudraCT: 2016-003726-17 (siehe EU klinisches Studienregister)

Vaccibody (VBN-01)

Title:An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
Indication:Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN
Type of study:Phase I
Contact: Sebastian Schülke (Kontaktperson)
[Sebastian.Schuelke@med.uni-heidelberg.de]
Investigator: PD Dr. med. Jürgen Krauss (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2017-002474-39 (siehe EU klinisches Studienregister)